跳至主要内容
临床试验/NL-OMON56339
NL-OMON56339尚未招募不适用

Assessment of myocardial function, endothelial function and perFUSION in early and advanced disease stages of Hypertrophic CardioMyopathy: FUSION-HCM - FUSION-HCM

Amsterdam UMC0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • MYBPC3 mutation carrier
  • MYH7 mutation carrier
  • Genotype-negative first degree relative of a MYBPC3 or MYH7 mutation carrier

排除标准

  • >=70 years old
  • Insulin-dependent diabetes mellitus
  • Claustrophobia
  • Pacemaker/ICD
  • Renal insufficiency <30 GFR
  • Hypertension (systolic >140mmHg or diastolic >90mmHg)
  • For the genotype negative group, no phenotype group, and mild phenotype group:
  • the use of blood pressure medication (diuretics, beta-blockers, ACE-inhibitors,
  • angiotensin II receptor blockers, calcium channel blockers, alpha blockers)
  • For the HCM phenotype group: when it is unsafe to withhold from blood pressure
  • medication (as specified above) for two days, as assessed by their own
  • cardiologist
  • Left ventricular outflow tract gradient > 50mmHg
  • Aortic valve disease
  • Left bundle branch block
  • (History of) Obstructive coronary artery disease
  • Chronic atrial fibrillation
  • Hormone replacement therapy
  • Second or third-degree AV-block, sick-sinussyndrome, prolonged QT-interval
  • Asthma and other obstructive pulmonary diseases
  • Previous adverse reaction to adenosine or dotarem

研究者

发起方
Amsterdam UMC

相似试验